MarketBeat reports USD 109.86 target for Integer Holdings stock

Published on 10/08/2026 at 20:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 464.11 million, down 2.60 percent. Integer Holdings stock costs EUR 113.50 after EUR 112.50.

Key points in brief

MarketBeat reported a USD 109.86 consensus price target and a Hold rating from 14 analysts on October 8, 2026.
Integer Holdings reported USD 464.11 million in second-quarter 2026 revenue and USD 0.69 in diluted earnings per share.
The Lang & Schwarz quote was EUR 113.50 on October 8, 2026, plus 0.89 percent versus EUR 112.50.
Integer Holdings is a NYSE-listed healthcare company focused on medical device contract manufacturing.

ITGR, US45826H1095, Illustration mit AI erstellt.

Integer Holdings (ISIN US45826H1095) was trading at EUR 113.50 at Lang & Schwarz on October 8, 2026, in after-hours trading, up 0.89 percent versus the EUR 112.50 prior close. The latest market signal is a USD 109.86 consensus price target, which MarketBeat reported on October 8, 2026.

Three takeover milestones shape ITGR

On August 3, 2026, Integer Holdings agreed to be acquired for USD 127.00 per share in a transaction valued at USD 4.4 billion, according to Simply Wall St. The agreement would take the company private after required shareholder and regulatory approvals.

On September 30, 2026, Integer Holdings received early termination of the Hart-Scott-Rodino waiting period for the KKR transaction, Simply Wall St reported. The remaining conditions include stockholder approval, further regulatory clearances and standard closing requirements.

On October 8, 2026, MarketBeat said 13 of 14 covering analysts rated Integer Holdings Hold and one rated it Buy. The average one-year target of USD 109.86 sits below the USD 127.00 cash consideration, highlighting the takeover price as the dominant valuation reference.

What does the USD 127 offer mean?

The offer gives investors a clear transaction benchmark, but the stock remains exposed to closing risk until the remaining approvals are completed. The proposed USD 127.00 cash payment is also close to the USD 126.35 share price cited by Simply Wall St on October 1, 2026.

Second-quarter figures set the operating backdrop

Integer Holdings generated USD 464.11 million in revenue during the second quarter of 2026, while diluted earnings per share were USD 0.69 and net income was USD 23.61 million. Revenue fell 2.60 percent year over year, and net income declined 36.00 percent from the second quarter of 2025, according to the reported financial data.

The operating picture was mixed: revenue exceeded the USD 451.07 million consensus estimate, while earnings per share came in below the USD 1.38 estimate cited by MarketBeat. That contrast matters because the takeover price now limits the relevance of short-term earnings surprises unless the deal fails or changes.

Next reporting date is October 29

ToAlpha lists October 29, 2026 as the next earnings date. Integer Holdings is a healthcare company specializing in medical device contract development and manufacturing, with products supporting cardiovascular, neuromodulation and other medical applications.

Stock stays near the offer value

Integer Holdings was trading at EUR 113.50 at Lang & Schwarz on October 8, 2026, in after-hours trading, up 0.89 percent versus the EUR 112.50 prior close. Its primary listing is on the NYSE, where the quoted currency is USD; the finance data snapshot places the 52-week range at USD 62.00 to USD 126.80 and market capitalization at USD 4.3 billion as of October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of Integer Holdings stock.